Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation

被引:50
作者
Makisalo, H
Koivusalo, A
Vakkuri, A
Hockerstedt, K
机构
[1] Univ Helsinki Hosp, Dept Surg, Div Transplantat & Liver Surg, FIN-00130 Helsinki, Finland
[2] Univ Helsinki Hosp, Dept Anesthesiol & Intens Care, Organ Transplantat Program, FIN-00130 Helsinki, Finland
关键词
D O I
10.1002/lt.20153
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver transplantation (LT) may be indicated in cirrhotic patients with underlying pulmonary artery hypertension. However, severe pulmonary artery hypertension with mean pulmonary artery pressure (mPAP) above 50 mmHg has even been considered a contraindication to LT. We present a cirrhotic patient with an mPAP of 56 mmHg measured using right heart catheterization (RHC) and with severely compromised physical capacity. She was first treated with sildenafil (Viagra(R)), a potent novel vasodilator, and successfully transplanted later. The mPAP decreased with sildenafil to the level of 28-31 mmHg and her general condition improved markedly. An LT using piggyback technique was performed 16 weeks later. Despite 2 reoperations for bleeding, the outcome has been excellent. In conclusion, treatment of severe portopulmonary hypertension (PHT) with sildenafil is effective. If a decrease in mPAP is achieved with sildenafil, it may improve the result of LT, even though no evidence of reversibility of PPHTN exists.
引用
收藏
页码:945 / 950
页数:6
相关论文
共 31 条
[1]  
ABENHAIM L, 1994, CHEST, V105, pS37
[2]  
[Anonymous], 1998, PRIMARY PULMONARY HY
[3]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[4]   Portopulmonary hypertension in decompensated cirrhosis with refractory ascites [J].
Benjaminov, FS ;
Prentice, M ;
Sniderman, KW ;
Siu, S ;
Liu, P ;
Wong, F .
GUT, 2003, 52 (09) :1355-1362
[5]   Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil [J].
Berkels, R ;
Klotz, T ;
Sticht, G ;
Englemann, U ;
Klaus, W .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 (04) :413-421
[6]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[7]  
Csete M, 1997, Liver Transpl Surg, V3, P454, DOI 10.1002/lt.500030422
[8]  
EVANGELOS D, 2003, CIRCULATION, V108, P2066
[9]   Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial [J].
Ghofrani, HA ;
Wiedemann, R ;
Rose, F ;
Schermuly, RT ;
Olschewski, H ;
Weissmann, N ;
Gunther, A ;
Walmrath, D ;
Seeger, W ;
Grimminger, F .
LANCET, 2002, 360 (9337) :895-900
[10]   PULMONARY-HYPERTENSION COMPLICATING PORTAL-HYPERTENSION - PREVALENCE AND RELATION TO SPLANCHNIC HEMODYNAMICS [J].
HADENGUE, A ;
BENHAYOUN, MK ;
LEBREC, D ;
BENHAMOU, JP .
GASTROENTEROLOGY, 1991, 100 (02) :520-528